NZ266525A - 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine derivatives and medicaments - Google Patents

4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine derivatives and medicaments

Info

Publication number
NZ266525A
NZ266525A NZ266525A NZ26652594A NZ266525A NZ 266525 A NZ266525 A NZ 266525A NZ 266525 A NZ266525 A NZ 266525A NZ 26652594 A NZ26652594 A NZ 26652594A NZ 266525 A NZ266525 A NZ 266525A
Authority
NZ
New Zealand
Prior art keywords
ethyl
oxo
tetrahydro
pyridine
pyrazolo
Prior art date
Application number
NZ266525A
Other languages
English (en)
Inventor
Allen Jacob Duplantier
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ266525A publication Critical patent/NZ266525A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ266525A 1993-07-06 1994-06-16 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine derivatives and medicaments NZ266525A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8829293A 1993-07-06 1993-07-06
PCT/IB1994/000156 WO1995001980A1 (en) 1993-07-06 1994-06-16 Bicyclic tetrahydro pyrazolopyridines

Publications (1)

Publication Number Publication Date
NZ266525A true NZ266525A (en) 1997-10-24

Family

ID=22210524

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ266525A NZ266525A (en) 1993-07-06 1994-06-16 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine derivatives and medicaments

Country Status (20)

Country Link
EP (1) EP0707585A1 (cg-RX-API-DMAC10.html)
JP (1) JP2944048B2 (cg-RX-API-DMAC10.html)
KR (1) KR100228949B1 (cg-RX-API-DMAC10.html)
CN (1) CN1048015C (cg-RX-API-DMAC10.html)
AU (1) AU695301B2 (cg-RX-API-DMAC10.html)
BR (1) BR9406946A (cg-RX-API-DMAC10.html)
CA (1) CA2166721C (cg-RX-API-DMAC10.html)
CZ (1) CZ3696A3 (cg-RX-API-DMAC10.html)
EG (1) EG20513A (cg-RX-API-DMAC10.html)
FI (1) FI943208L (cg-RX-API-DMAC10.html)
HU (1) HUT74170A (cg-RX-API-DMAC10.html)
IL (1) IL110175A (cg-RX-API-DMAC10.html)
MX (1) MX9405132A (cg-RX-API-DMAC10.html)
NO (1) NO305029B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ266525A (cg-RX-API-DMAC10.html)
PL (1) PL312426A1 (cg-RX-API-DMAC10.html)
RU (1) RU2131876C1 (cg-RX-API-DMAC10.html)
TW (1) TW316904B (cg-RX-API-DMAC10.html)
WO (1) WO1995001980A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA944844B (cg-RX-API-DMAC10.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ292991A (en) * 1994-10-20 1999-02-25 Pfizer Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them
DE69525978T2 (de) * 1995-06-06 2002-12-19 Pfizer Trizyclische 5,6-dihydro-9h-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-alpha)pyridine
AP932A (en) * 1996-08-26 2001-02-02 Pfizer Tricyclic 5,6-dihydro-9H-pyrazolo (3,4c)-1,2,4,-triazolo (4,3-a) pyridines.
JP3554337B2 (ja) * 1996-09-04 2004-08-18 ファイザー・インク インダゾール誘導体、およびホスホジエステラーゼ（ｐｄｅ）タイプ４と腫瘍壊死因子（ｔｎｆ）産生の阻害剤としてのインダゾール誘導体の使用
IL158649A0 (en) * 1997-09-26 2004-05-12 Zentaris Gmbh Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
IL142959A0 (en) 1998-12-23 2002-04-21 Du Pont Pharm Co Nitrogen containing heterobicycles as factor xa inhibitors
US6326495B2 (en) 1999-04-30 2001-12-04 Pfizer Inc. Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
EP1671651B1 (en) 1999-08-21 2009-11-11 Nycomed GmbH Synergistic combination of pumafentrine and salmeterol
TWI243055B (en) * 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
BR0113176A (pt) * 2000-08-10 2003-06-17 Pharmacia Italia Spa Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos
DE60118004T2 (de) * 2000-08-14 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Substituierte pyrazole
US6960595B2 (en) * 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
US6750225B2 (en) 2001-04-18 2004-06-15 Bristol-Myers Squibb Pharms Company 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
CA2441772A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones as factor xa inhibitors
JP4196678B2 (ja) * 2001-04-26 2008-12-17 味の素株式会社 複素環化合物
IL160693A0 (en) * 2001-09-21 2004-08-31 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7468376B2 (en) 2003-02-27 2008-12-23 Palau Pharma, S.A. Pyrazolopyridine derivates
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR050188A1 (es) * 2004-08-03 2006-10-04 Uriach Y Compania S A J Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
DE102005031580A1 (de) * 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituierte Sulfolanylpyrazole und ihre Verwendung
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
BR112016002789A2 (pt) 2013-08-09 2017-11-21 Ardelyx Inc compostos e métodos para inibir transporte de fosfato
CN110357888A (zh) * 2018-04-09 2019-10-22 南京药捷安康生物科技有限公司 杂环磷酸二酯酶抑制剂及其用途
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365459A (en) * 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
FR1463883A (fr) * 1964-09-08 1966-07-22 Ciba Geigy Procédé de préparation de triaza-composés bicycliques
US3340269A (en) * 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
HU183325B (en) * 1981-02-11 1984-04-28 Richter Gedeon Vegyeszet Process for preparing new apovincaminol-3',4',5'-trimethoxy-benzoates substituted with a nitro group
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
FR2525602A1 (fr) * 1982-04-21 1983-10-28 Synthelabo Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines

Also Published As

Publication number Publication date
FI943208A7 (fi) 1995-01-07
MX9405132A (es) 1995-01-31
RU2131876C1 (ru) 1999-06-20
FI943208A0 (fi) 1994-07-05
HUT74170A (en) 1996-11-28
KR960703852A (ko) 1996-08-31
AU6805794A (en) 1995-02-06
CA2166721C (en) 1999-07-27
EP0707585A1 (en) 1996-04-24
WO1995001980A1 (en) 1995-01-19
NO960056L (no) 1996-01-05
EG20513A (en) 1999-06-30
NO960056D0 (no) 1996-01-05
BR9406946A (pt) 1996-08-06
CA2166721A1 (en) 1995-01-19
CN1048015C (zh) 2000-01-05
TW316904B (cg-RX-API-DMAC10.html) 1997-10-01
CZ3696A3 (en) 1997-06-11
IL110175A0 (en) 1994-10-07
ZA944844B (en) 1996-01-05
FI943208L (fi) 1995-01-07
NO305029B1 (no) 1999-03-22
PL312426A1 (en) 1996-04-29
JPH08507084A (ja) 1996-07-30
HU9503934D0 (en) 1996-03-28
IL110175A (en) 2000-01-31
JP2944048B2 (ja) 1999-08-30
CN1129940A (zh) 1996-08-28
AU695301B2 (en) 1998-08-13
KR100228949B1 (ko) 1999-11-01

Similar Documents

Publication Publication Date Title
NZ266525A (en) 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine derivatives and medicaments
US5508300A (en) Dihydro pyrazolopyrroles, compositions and use
AU702105B2 (en) Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
EP0672031B1 (en) Catechol diethers as selective pde iv inhibitors
EP0730588B1 (en) Isoxazoline compounds as antiinflammatory agents
KR100339935B1 (ko) 치환된 인다졸 유도체, 및 포스포디에스테라제 4형 및 종양괴사 인자 형성의 억제제로서의 그의 용도
WO2001019802A1 (fr) Composes cycliques aromatiques azotes a six elements
MXPA98008897A (es) Compuestos inhibidores de enzima fosfodiesterasa tipo 1.
KR20000022516A (ko) 치환된 인다졸 유도체 및 포스포디에스테라제 4형 및 종양 괴사인자 억제제로서 그의 용도
CA2438294C (en) Pyridopyrimidine or naphthyridine derivative
AP609A (en) Tricyclic 5,6-dihydro-9H-pyrazolo[3,4c]-1,2,4-triazolo[4,3-A]pyridines.
JP2002338466A (ja) 医薬組成物
AU2003226680B2 (en) Phthalimido derivatives as inhibitors of monoamine oxidase B
JP2004083587A (ja) 医薬組成物
AU9240298A (en) Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
CA2201728A1 (en) Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
AP932A (en) Tricyclic 5,6-dihydro-9H-pyrazolo (3,4c)-1,2,4,-triazolo (4,3-a) pyridines.